Antibacterial cosmetic composition for acne bacteria

Abstract

The present invention relates to an antibacterial cosmetic composition for acne bacteria. According to the present invention, provided is a cosmetic composition which is safe to the human body and exhibits antibacterial activity against acne bacteria.

Description

Antibacterial cosmetic composition for acne bacteria

[0001] Cross-citation with related applications

[0002] This application claims the benefit of priority based on Korean Patent Application No. 10-2024-0165340 filed November 19, 2024 and Korean Patent Application No. 10-2025-0155070 filed October 23, 2025, and all contents disclosed in the documents of said Korean patent applications are incorporated herein as part of this specification.

[0003]

[0004] The present invention relates to a cosmetic composition having antibacterial activity against acne bacteria.

[0005]

[0006] Acne is a chronic inflammatory disease of the sebaceous glands in which sebum secretion is not carried out smoothly due to keratin retention hyperkeratosis in the pores.

[0007] Acne can occur due to the combined action of various mechanisms, such as increased sebum secretion, constriction of hair follicles caused by hyperkeratosis, proliferation of acne bacteria, and inflammatory response.

[0008] Medications such as oral and topical agents are primarily used to suppress and alleviate the occurrence of acne. Examples include treatment methods based on the anti-inflammatory action of anti-inflammatory analgesics, methods to suppress sebum production using male hormone inhibitors, methods using exfoliating agents such as retinoic acid and benzoyl peroxide, and methods to inhibit the activity of acne bacteria using antibacterial agents.

[0009] However, while the aforementioned methods can achieve some degree of effectiveness in treating acne, they have issues regarding side effects. For example, the use of hormones has been reported to cause side effects such as inhibition of epidermal growth, the use of exfoliants raises concerns about skin irritation and contact dermatitis, and the use of antibacterial agents is known to lead to the emergence of resistant bacteria and the potential for photosensitivity.

[0010] Therefore, research and development of products that can effectively improve acne while maintaining human safety are still required.

[0011]

[0012] The present invention is intended to provide a cosmetic composition that is safe for the human body and exhibits antibacterial activity against acne bacteria.

[0013]

[0014] According to one embodiment of the invention, an antibacterial cosmetic composition for acne bacteria is provided, comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0015] According to another embodiment of the invention, the use of 3-hydroxypropionic acid or a derivative thereof is provided for the preparation of an acne bacteria antibacterial cosmetic composition.

[0016] According to another embodiment of the invention, a method for inhibiting the activity of acne bacteria is provided using a cosmetic composition comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0017]

[0018] Hereinafter, the above-described antibacterial cosmetic composition for acne bacteria according to an embodiment of the invention will be described in more detail.

[0019]

[0020] Terms and words used in this specification and claims should not be interpreted as being limited to their ordinary or dictionary meanings, but should be interpreted in a meaning and concept consistent with the technical idea of ​​the invention, based on the principle that the inventor can appropriately define the concept of the terms to best describe his invention.

[0021] Unless otherwise defined in this specification, all technical and scientific terms have the same meaning as generally understood by those skilled in the art to which the invention pertains. The terms used in the description of the invention are merely for the purpose of effectively describing specific embodiments and are not intended to limit the invention.

[0022] The present invention is capable of various modifications and may take various forms, and specific embodiments are illustrated and described in detail below. However, this is not intended to limit the invention to the specific disclosed forms, and it should be understood that the invention includes all modifications, equivalents, and substitutions that fall within the spirit and scope of the invention.

[0023] The singular forms used in this specification include plural forms unless the phrases clearly indicate otherwise.

[0024] As used in this specification, the meaning of “includes” specifies certain characteristics, regions, integers, steps, actions, elements, and / or components, and does not exclude the existence or addition of other specific characteristics, regions, integers, steps, actions, elements, components, and / or groups.

[0025] In this specification, when temporal sequences are described, for example, using expressions such as 'after,' 'following,' 'next,' or 'before,' cases that are not continuous may be included unless expressions such as 'immediately' or 'directly' are used.

[0026] In this specification, "derivative" refers to a compound that has been modified from a parent compound of an organic compound through reactions such as the introduction of functional groups, oxidation, reduction, or substitution of atoms, to the extent that the structure and properties of the parent compound are not significantly altered.

[0027] In this specification, the term "containing as an active ingredient" means that the composition according to an embodiment of the invention contains 3-hydroxypropionic acid or a derivative thereof in an amount sufficient to achieve an antibacterial effect.

[0028] In addition, the term "antimicrobial" in this specification means the ability to prevent, reduce, or inhibit the growth or survival of microorganisms such as bacteria and fungi.

[0029]

[0030] As a result of the inventors' continued research, it was confirmed that 3-hydroxypropionic acid has human safety and can exhibit antibacterial activity against acne bacteria.

[0031] In particular, 3-hydroxypropionic acid exhibits antibacterial activity against Propionibacterium acnes (KCCM 41747), an acne bacterium, and can be suitably used as an active ingredient in an antibacterial cosmetic composition that can effectively improve acne.

[0032]

[0033] According to one embodiment of the invention, an antibacterial cosmetic composition for acne bacteria is provided, comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0034]

[0035] The above antibacterial cosmetic composition for acne bacteria comprises 3-hydroxypropionic acid or a derivative thereof as an active ingredient. Preferably, the above antibacterial cosmetic composition for acne bacteria comprises 3-hydroxypropionic acid as an active ingredient.

[0036]

[0037] 3-hydroxypropionic acid synthesized by chemical or biological methods can be used as an active ingredient.

[0038] According to one embodiment, 3-hydroxypropionic acid obtained through a biological process, such as fermenting a strain capable of producing 3-hydroxypropionic acid, may preferably be used as the active ingredient. The 3-hydroxypropionic acid obtained by the above method is a radiocarbon isotope ( 14 It may include C).

[0039] Preferably, the active ingredient may have a radiocarbon isotope content of 20 pMC (percent modern carbon) or more as measured by ASTM D6866-21, and a biocarbon content of 20 weight% or more. Specifically, the active ingredient may have a radiocarbon isotope content of 20 pMC or more, or 50 pMC or more, or 90 pMC or more, or 100 pMC or more, or 90 to 110 pMC as measured by ASTM D6866-21; and the biocarbon content may be 20 weight% or more, or 50 weight% or more, or 80 weight% or more, or 90 weight% or more, or 95 weight% or more, or 90 to 100 weight%.

[0040] The above radiocarbon isotope content (pMC) is the radiocarbon isotope contained in 3-hydroxypropionic acid ( 14 C) and radiocarbon isotopes of modern standard reference materials ( 14 It refers to the ratio of C). For reference, since the effect of the nuclear testing program of the 1950s is still ongoing and has not been extinguished, the above radiocarbon content (pMC) may be greater than 100%.

[0041] The above biocarbon content represents the biocarbon content relative to the total carbon content contained in 3-hydroxypropionic acid, and the higher this value, the more environmentally friendly the compound may be.

[0042] If the radiocarbon content (pMC) and biocarbon content of the above 3-hydroxypropionic acid are excessively low, the eco-friendliness is reduced and it may not be considered a bio-derived material.

[0043] Radiocarbon isotopes ( 14 C) contains 1 x 10 carbon atoms in the Earth's atmosphere 12 There is about 1 per unit, with a half-life of about 5,700 years, and cosmic rays and ordinary nitrogen ( 14 It can exist abundantly in the upper atmosphere due to nuclear reactions in which N participates.

[0044] In fossil fuels, radioactive carbon isotopes decayed a long time ago 14 The C ratio can be practically zero. When bio-derived materials are used as raw materials for 3-hydroxypropionic acid, or when fossil fuels are used in combination with it, the content of radiocarbon isotopes (pMC) and biocarbon contained in 3-hydroxypropionic acid can be measured according to ASTM D6866-21.

[0045] For example, the measurement method may involve converting carbon atoms contained in the target compound into the form of graphite or carbon dioxide gas and measuring them using a mass spectrometer, or measuring them according to liquid scintillation spectroscopy. At this time, 14 C ions 12 An accelerator can be used to separate from C ions, and the two isotopes can be separated and their content and content ratio measured by a mass spectrometer.

[0046]

[0047] In this specification, derivatives of 3-hydroxypropionic acid refer to compounds that are chemically modified while maintaining the antibacterial activity of 3-hydroxypropionic acid. Such derivatives include compounds formed by substituting one or more of the carboxyl groups (-COOH) or hydroxyl groups (-OH) within the molecule of 3-hydroxypropionic acid.

[0048] Although 3-hydroxypropionic acid itself exhibits excellent antibacterial activity, it may not disperse uniformly in various cosmetic formulations, such as oil-in-water (O / W) or water-in-oil (W / O), or may impair formulation stability. To minimize these phenomena, derivatives of 3-hydroxypropionic acid may be used. For example, hydrophobic derivatives enable stable dispersion in oil-soluble formulations, while hydrophilic derivatives are advantageous for exhibiting uniform antibacterial activity in water-soluble formulations.

[0049] However, it is preferable that the above derivative does not contain phenyl group substituents. This is because phenyl group-containing compounds may cause potential skin irritation or toxicity, making them unsuitable for long-term use, and there is a concern that they may reduce the chemical stability of the derivative, thereby lowering the storage stability of the cosmetic.

[0050] For example, the derivative may be a salt formed by combining the carboxyl group of 3-hydroxypropionic acid with an alkali metal cation such as sodium, potassium, calcium, etc., or an organic cation such as ammonium. These salts can increase water solubility to improve stability within the formulation and exhibit the effect of increasing biocompatibility.

[0051] As another example, the derivative may be an ester compound in which the carboxyl or hydroxyl group of 3-hydroxypropionic acid is bonded to an alkyl or acyl group through an ester bond. In particular, C1-C10 alkyl esters are preferred, and examples may include methyl esters, ethyl esters, butyl esters, hexyl esters, etc. Such ester derivatives increase hydrophobicity, thereby improving stability in formulations such as emulsions and facilitating the control of skin absorption rates.

[0052] As another example, the derivative may be an amide compound in which the carboxyl group of 3-hydroxypropionic acid is bonded to an amine through an amide bond, or a lactone-type derivative in which 3-hydroxypropionic acid forms a cyclic ester structure through an intramolecular dehydration reaction.

[0053] As another example, the derivative may be a glyceryl ester of 3-hydroxypropionic acid and a polyethylene glycol (PEG) ester. These derivatives may combine with glycerin or PEG, which act as thickeners and moisturizers in the formulation, to simultaneously improve the function of the active ingredient and the physical properties of the formulation.

[0054] Preferably, the derivative may be an alkali metal salt of 3-hydroxypropionic acid or a C1-C10 alkyl ester.

[0055] The above derivative may preferably have a molecular weight of 95 Da to 500 Da. To prevent reduced stability or difficulty in handling after synthesis, it is preferable for the above derivative to have a molecular weight of 95 Da or more. However, if the molecular weight of the above derivative is too high, the skin penetration rate may be significantly reduced, which may decrease antibacterial activity against acne bacteria or reduce solubility within the formulation. Therefore, it is preferable for the above derivative to have a molecular weight of 500 Da or less.

[0056] The salt derivative of the above 3-hydroxypropionic acid can be obtained as a salt of the corresponding metal by reacting 3-hydroxypropionic acid with a basic substance such as sodium hydroxide (NaOH), potassium hydroxide (KOH), or calcium hydroxide (Ca(OH)2) in a water or alcohol solvent and neutralizing it. The reaction can be carried out at room temperature or under heating conditions, and the desired salt form can be synthesized by adjusting the pH.

[0057] The ester derivative of the above 3-hydroxypropionic acid can be prepared through a Fischer esterification reaction in which the carboxyl group (-COOH) of 3-hydroxypropionic acid is reacted with an alcohol (e.g., methanol, ethanol, butanol, etc.). This reaction can be carried out in the presence of an acid catalyst such as sulfuric acid (H2SO4) or p-toluenesulfonic acid (p-TsOH).

[0058]

[0059] The above antibacterial cosmetic composition for acne bacteria may have antibacterial activity against acne bacteria through the action of the above active ingredient. Specifically, the above antibacterial cosmetic composition for acne bacteria may exhibit antibacterial activity against Propionibacterium acnes (KCCM 41747).

[0060]

[0061] According to one embodiment, the acne bacteria antibacterial cosmetic composition may contain 0.1% to 10% by weight of the active ingredient based on the total weight of the acne bacteria antibacterial cosmetic composition.

[0062] Specifically, the acne bacteria antibacterial cosmetic composition may comprise 0.1% by weight or more, or 0.2% by weight or more, or 0.3% by weight or more, or 0.4% by weight or more, or 0.5% by weight or more, based on the total weight of the acne bacteria antibacterial cosmetic composition; and 10% by weight or less, or 9% by weight or less, or 8% by weight or less, or 7% by weight or less, or 6% by weight or less, or 5% by weight or less of the active ingredient.

[0063] In order to sufficiently express an antibacterial effect through the action of the above active ingredient, it is preferable that the acne bacteria antibacterial cosmetic composition contains at least 0.1% by weight, or at least 0.2% by weight, or at least 0.3% by weight, or at least 0.4% by weight, or at least 0.5% by weight of the above active ingredient.

[0064] However, if the above active ingredient is included in an excessive amount, side effects such as increased skin irritation may occur and the formulation stability of the cosmetic may be compromised. Therefore, it is preferable that the above antibacterial cosmetic composition for acne bacteria contains the above active ingredient in an amount of 10% by weight or less, or 9% by weight or less, or 8% by weight or less, or 7% by weight or less, or 6% by weight or less, or 5% by weight or less.

[0065] Preferably, the acne bacteria antibacterial cosmetic composition may contain 0.1% to 10% by weight, or 0.2% to 10% by weight, or 0.2% to 9% by weight, or 0.3% to 9% by weight, or 0.3% to 8% by weight, or 0.4% to 8% by weight, or 0.4% to 7% by weight, or 0.5% to 7% by weight, or 0.5% to 6% by weight, or 0.5% to 5% by weight, based on the total weight of the acne bacteria antibacterial cosmetic composition.

[0066]

[0067] According to one embodiment, the antibacterial cosmetic composition for acne bacteria may have a cosmetic formulation conventional in the art to which the present invention belongs. For example, the antibacterial cosmetic composition for acne bacteria may have a formulation that is a solution, suspension, emulsion, paste, gel, cream, lotion, powder, oil, foam, pack, spray, aerosol, balm, solid soap, liquid soap, powder foundation, emulsion foundation, or wax foundation.

[0068] According to one embodiment, the antibacterial cosmetic composition for acne bacteria may include, in addition to the active ingredient, an organic solvent, a fatty substance, a solvent, a thickener, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an emulsifier, a filler, a chelating agent, a preservative, a vitamin, a humectant, a dye, a pigment, a hydrophilic or lipophilic active agent, etc. Additionally, the antibacterial cosmetic composition for acne bacteria may contain an auxiliary agent commonly used in the fields of cosmetics or dermatology.

[0069]

[0070] The above antibacterial cosmetic composition for acne bacteria may further include a physiologically acceptable medium consisting of water or a mixture of an organic solvent and water.

[0071] For example, the organic solvent may include C1-C4 lower alcohols such as ethanol and isopropyl alcohol, alkylene glycols such as ethylene glycol and propylene glycol, ethylene glycol monomethyl ether, monoethyl ether, monobutyl ether, propylene glycol, etc. The physiologically acceptable medium may be applied in an amount of 1 to 90 weight percent based on the total weight of the acne bacteria antibacterial cosmetic composition.

[0072] The above medium may be thickened using a thickener commonly used in the cosmetics field. The thickener may be applied in an amount of 0.1 to 5 weight percent based on the total weight of the composition.

[0073] In addition, according to various embodiments of the above-described antibacterial cosmetic composition for acne bacteria, a person skilled in the art may select an auxiliary agent generally required to manufacture such composition. For example, the auxiliary agent may include a stabilizer, a pH adjuster, an osmotic pressure modifier, an emulsifying agent, a sunscreen agent, an antioxidant, a fragrance, anionic surfactant, cationic surfactant, nonionic surfactant, an amphoteric surfactant, etc.

[0074]

[0075] According to one embodiment, when the formulation of the antibacterial cosmetic composition for acne bacteria is a powder or a spray, it may include a carrier component such as lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc.

[0076] According to one embodiment, when the formulation of the antibacterial cosmetic composition for acne bacteria is a paste, gel, or cream, it may include a carrier component such as animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc.

[0077] According to one embodiment, when the formulation of the antibacterial cosmetic composition for acne bacteria is a solution or an emulsion, it may include a carrier component such as a solvent, a solubilizer, or an emulsifying agent. For example, the solution or emulsion formulation may include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan.

[0078] According to one embodiment, when the formulation of the antibacterial cosmetic composition for acne bacteria is a suspension, a liquid diluent such as water, ethanol, or propylene glycol; a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester; and microcrystalline cellulose, aluminum metahydroxide, bentonite, etc. may be applied.

[0079] According to one embodiment, when the formulation of the acne bacteria antibacterial cosmetic composition is a cleansing agent containing a surfactant, it may include a carrier component such as an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, isethionate, an imidazolinium derivative, sodium methyl cocoyl taurate, sodium lauroyl sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, an aliphatic alcohol, a fatty acid glyceride, a fatty acid diethanolamide, vegetable oil, a lanolin derivative, an ethoxylated glycerol fatty acid ester, etc.

[0080]

[0081] According to another embodiment of the invention, the use of 3-hydroxypropionic acid or a derivative thereof is provided for the preparation of an acne bacteria antibacterial cosmetic composition.

[0082] Preferably, the use of 3-hydroxypropionic acid or a derivative thereof is provided for the preparation of the above-described antibacterial cosmetic composition for acne bacteria.

[0083] 3-hydroxypropionic acid exhibits antibacterial activity against acne bacteria, so a cosmetic composition containing 3-hydroxypropionic acid or a derivative thereof as an active ingredient can be used to alleviate or improve symptoms caused by acne bacteria.

[0084] In the above application, the active ingredient 3-hydroxypropionic acid or a derivative thereof may be used in an amount of 0.1% to 10% by weight based on the total weight of the acne bacteria antibacterial cosmetic composition.

[0085] In order to ensure that the antibacterial effect is sufficiently expressed through the action of the above active ingredient, it is preferable that the above active ingredient be used in an amount of 0.1% by weight or more, or 0.2% by weight or more, or 0.3% by weight or more, or 0.4% by weight or more, or 0.5% by weight or more, based on the total weight of the acne bacteria antibacterial cosmetic composition. However, if the above active ingredient is used in an excessive amount, side effects such as increased skin irritation may occur, and the formulation stability of the cosmetic may be compromised. Therefore, it is preferable that the above active ingredient be used in an amount of 10% by weight or less, or 9% by weight or less, or 8% by weight or less, or 7% by weight or less, or 6% by weight or less, or 5% by weight or less, based on the total weight of the acne bacteria antibacterial cosmetic composition. Preferably, the active ingredient may be used in an amount of 0.1% to 10% by weight, or 0.2% to 10% by weight, or 0.2% to 9% by weight, or 0.3% to 9% by weight, or 0.3% to 8% by weight, or 0.4% to 8% by weight, or 0.4% to 7% by weight, or 0.5% to 7% by weight, or 0.5% to 6% by weight, or 0.5% to 5% by weight, based on the total weight of the acne bacteria antibacterial cosmetic composition.

[0086]

[0087] According to another embodiment of the invention, a method for inhibiting the activity of acne bacteria is provided by using a cosmetic composition comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient. Specifically, a method for inhibiting the activity of the acne bacterium Propionibacterium acnes (KCCM 41747) is provided by using a cosmetic composition comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0088] Preferably, the method of inhibiting the activity of acne bacteria may be carried out using the aforementioned antimicrobial cosmetic composition for acne bacteria. The method may be carried out by applying the cosmetic composition to a part of the human body where inhibition of acne bacteria activity is required. The method may be carried out for 1 to 6 months, 1 to 7 days a week, with an application frequency of 1 to several times a day (e.g., 1 to 5 times or 1 to 3 times).

[0089]

[0090] According to the present invention, a cosmetic composition having human safety and exhibiting antibacterial activity against acne bacteria is provided.

[0091]

[0092] The operation and effects of the invention will be explained in more detail through the specific embodiments described below. However, these are presented merely as examples to aid in understanding the invention. The following embodiments are not intended to limit the scope of the invention in any way, and it will be obvious to those skilled in the art that various changes and modifications are possible within the scope and technical spirit of the invention.

[0093]

[0094] Preparation Example 1

[0095] A recombinant vector was prepared by introducing genes encoding glycerol dehydratase and aldehyde dehydrogenase, which are known to produce 3-hydroxypropionic acid using glycerol as a substrate. The recombinant vector was introduced into the E. coli W3110 strain to produce a strain for 3-hydroxypropionic acid production.

[0096] Specifically, the BtuR gene encoding adenosyltransferase was cloned into the plasmid pCDF containing the gene encoding glycerol dehydratase (dhaB), the gene encoding aldehyde dehydrogenase (aldH), and the gene encoding glycerol dehydratase reactivase (gdrAB) to obtain the vector pCDF_J23101_dhaB_gdrAB_J23100_aldH_btuR. The vector was introduced into the W3110 strain (KCCM 40219) by electroporation using an electroporation device (Bio-Rad, Gene Pulser Xcell) to construct a strain for producing 3-hydroxypropionic acid.

[0097] The above strain for producing 3-hydroxypropionic acid was fermented and cultured in a 10 L fermenter at 35 ℃ using unrefined glycerol as a carbon source to produce 3-hydroxypropionic acid. To prevent a decrease in pH caused by the production of 3-hydroxypropionic acid, calcium hydroxide (Ca(OH)2), an alkali metal salt, was added to maintain the pH at a neutral level during fermentation.

[0098] After fermentation culture, cells were removed by centrifugation (4000 rpm, 10 min, 4 ℃), and primary purification was performed using activated carbon. The 3-hydroxypropionic acid concentration of the fermented liquid after the primary purification was 100 g / L, and it was concentrated to 650 g / L using a rotary evaporator (50 ℃, 50 mbar) and stirred at room temperature (300 rpm) to produce Ca(3HP)2 crystals.

[0099] The crystal was washed five times with ethanol and dried in an oven at 45°C to finally recover the crystal. The weight of the crystal was measured, and the crystal was dissolved in water to obtain 3-hydroxypropionic acid (3HP) using high-performance liquid chromatography (HPLC).

[0100]

[0101] Preparation Example 2

[0102] 3-hydroxypropionic acid (3HP) was obtained in substantially the same manner as in Preparation Example 1, except that Mg(OH)2 was used instead of Ca(OH)2 as the alkali metal salt.

[0103]

[0104] Example 1

[0105] A cosmetic composition was prepared by mixing 1 wt% of 3-hydroxypropionic acid obtained in Preparation Example 1, 0.6 wt% of hydroxyethyl cellulose, 2.5 wt% of cetostearyl alcohol, 2.5 wt% of stearyl triethylammonium chloride, and the remainder of purified water (total 100 wt%).

[0106]

[0107] Example 2

[0108] A cosmetic composition was prepared by mixing 2 wt% of 3-hydroxypropionic acid obtained in Preparation Example 1 above, 0.8 wt% of hydroxyethyl cellulose, 2 wt% of cetostearyl alcohol, 3 wt% of stearyl triethylammonium chloride, and the remainder of purified water.

[0109]

[0110] Example 3

[0111] A cosmetic composition was prepared by mixing 5 wt% of the 3-hydroxypropionic acid obtained in Preparation Example 1 above, 50 wt% of ethanol, 3.5 wt% of glycerin, 4.5 wt% of castor oil, and the remainder of purified water.

[0112]

[0113] Example 4

[0114] A cosmetic composition was prepared by mixing 0.5 wt% of 3-hydroxypropionic acid obtained in Preparation Example 1 above, 55 wt% of ethanol, 5 wt% of glycerin, 5 wt% of castor oil, and the remainder of purified water.

[0115]

[0116] Example 5

[0117] A cosmetic composition, which is a softening lotion (skin lotion), is prepared by mixing 0.5 wt% of 3-hydroxypropionic acid obtained in Preparation Example 1 above, 3 wt% of glycerin, 2 wt% of butylene glycol, 2 wt% of propylene glycol, 0.1 wt% of polyacrylic acid, 0.2 wt% of polyethylene glycol-12 nonylphenyl ether, 0.4 wt% of polysorbate-80, 10 wt% of ethanol, 0.1 wt% of triethanolamine, and the remainder of purified water.

[0118]

[0119] Example 6

[0120] A cosmetic composition, which is a nourishing cosmetic (milk lotion), is prepared by mixing 1 wt% of 3-hydroxypropionic acid obtained in Preparation Example 1 above, 3 wt% of glycerin, 3 wt% of butylene glycol, 0.5 wt% of liquid paraffin, 4 wt% of beeswax, 5 wt% of caprylic / capric triglyceride, 5 wt% of squalene, 1.5 wt% of polysorbate-60, 1 wt% of cetearyl alcohol, 1.5 wt% of sorbitan sesquioleate, 0.1 wt% of polyacrylic acid, 0.2 wt% of triethanolamine, and the remainder of purified water.

[0121]

[0122] Example 7

[0123] A cosmetic composition in the form of a nourishing cream is prepared by mixing 2 wt% of 3-hydroxypropionic acid obtained in Preparation Example 1 above, 3 wt% of glycerin, 3 wt% of butylene glycol, 7 wt% of liquid paraffin, 7 wt% of beta-glucan, 3 wt% of caprylic / capric triglyceride, 5 wt% of squalene, 1.5 wt% of cetearyl glucoside, 1.2 wt% of polysorbate-60, 0.4 wt% of sorbitan stearate, 0.1 wt% of polyacrylic acid, 0.1 wt% of triethanolamine, and the remainder of purified water.

[0124]

[0125] Experimental Example 1

[0126] (Measurement of radiocarbon isotopes and biocarbon content)

[0127] The radiocarbon isotope content (pMC) and biocarbon content of the 3-hydroxypropionic acid obtained in Preparation Examples 1 and 2 above were measured using ASTM D6866-21 (Method B).

[0128] The above biocarbon content refers to the content of biocarbon contained in the 3-hydroxypropionate crystals obtained in Preparation Examples 1 and 2, and the radiocarbon isotope ratio (pMC) refers to the radiocarbon isotope contained in the 3-hydroxypropionate crystals ( 14 C) and radiocarbon isotopes of modern standard reference materials ( 14 It refers to the ratio of C).

[0129]

[0130] Concentration Concentration (g / L) Radiocarbon Isotope Ratio (pMC) Biocarbon Content (Wet%) Preparation Example 16 50 10 2.72 100 Preparation Example 28 50 10 3.25 100

[0131] Referring to Table 1 above, it was confirmed that both 3HP salt crystals of Preparation Examples 1 and 2 had a radiocarbon isotope ratio of 102 pMC or higher and a biocarbon content of 100 wt%.

[0132]

[0133] Experimental Example 2

[0134] (Skin tissue cell stability test)

[0135] 1) Explant tissue culture

[0136] Human skin tissue provided for research purposes (IRB No. 4-2023-0054; Institutional Review Board, Severance Medical Center, Yonsei University College of Medicine) was cleaned of fat and washed several times with PBS (phosphate buffered saline; Lonza) to remove residual impurities. After preparing the tissues in a size of 1 cm × 1 cm for each test group, the sample solution was applied to the prepared skin tissues, while PBS was applied to the negative control. Here, the sample solution was prepared by mixing 3-hydroxypropionic acid (3HP) obtained in Preparation Example 1 with phosphate buffered saline (PBS) to obtain compositions with 3HP concentrations of 5 wt%, 2 wt%, 1 wt%, and 0.5 wt%. Skin tissues that had absorbed the sample solution were cultured in a dedicated medium at 37°C and 5% CO2.

[0137] 2) HE (Hematoxylin eosin) staining

[0138] Tissues obtained 24 hours after application of the sample solution were fixed with 10% formalin, and paraffin blocks and paraffin-embedded slides were prepared. The nuclei of the deparaffinized tissues were stained with hematoxylin (S3309; dako) solution and then washed with running water. The cytoplasm was stained with Eosin (318906; sigma) solution and washed. The completely dehydrated tissues were then fixed using mounting solution, and the epidermis and papillary dermis of the fixed tissues were observed by photographing them at 400x magnification using an optical microscope (BX43F; OLYMPUS).

[0139] As a result, no damage to the epidermis and dermis or separation between tissues was observed in the skin tissue to which the above sample solution was applied.

[0140]

[0141] Experimental Example 3

[0142] (Preparation of bacterial solution)

[0143] Propionibacterium acnes (KCCM 41747) is inoculated into RCM medium and placed in an anaerobe pouch system to create an anaerobic environment, where it is incubated for 7 days at 37°C. The cultured test bacteria are collected, streaked onto reinforced clostridial agra, and the resulting plate is placed in an anaerobe pouch system and incubated in a 37°C incubator for 7 days. Using the same method, only the active cultured bacteria are collected and used from secondary and tertiary cultures. The active cultured bacteria are added to 2 mL of reinforced clostridial medium, mixed, placed in an anaerobe pouch system, and incubated statically in a 37°C incubator. The cultured bacteria are added to TSB medium, and 1 x 10⁶ bacteria are added per 1 mL of bacterial suspension. 5 After diluting to CFU, the supernatant is removed by centrifugation (9300 RCF, 1 min) to prepare the bacterial suspension.

[0144] (Measurement of bacterial inhibition rate)

[0145] Referring to the "Guidelines for the Efficacy Evaluation of External Disinfectants (Quasi-drugs)" published by the Ministry of Food and Drug Safety of the Republic of Korea, the bacterial inhibition rate of the sample solution against the above bacterial solution was measured. Here, the sample solution used was a composition in which 3-hydroxypropionic acid (3HP) obtained in Preparation Example 1 was mixed with phosphate-buffered physiological saline (PBS) to have 3HP concentrations of 5 wt%, 2 wt%, 1 wt%, and 0.5 wt%.

[0146] Specifically, a test group is prepared by adding 1 mL of the sample solution to the bacterial suspension and suspending it, then leaving it at room temperature for 5 minutes. A negative control is prepared by adding 1 mL of PBS to the bacterial suspension and suspending it at room temperature for 5 minutes. A positive control is prepared by adding 0.5 units of Penicillin G sodium salt to the bacterial suspension and suspending it at room temperature for 5 minutes.

[0147] After centrifuging the above test group, negative control group, and positive control group (9300 RCF, 1 min) respectively, the supernatant is removed, and 1 mL of PBS buffer is added to suspend the precipitate. After repeating the washing process twice under the above conditions, 1 mL of PBS buffer is finally added to the precipitate to suspend it. 0.1 mL of each sample is spread onto three TSA media so that approximately 30 to 300 colonies are observed on the negative control standard agar medium, and the samples are incubated at 37°C for 7 days. Subsequently, the number of formed colonies is counted, and the bacterial inhibition rate of the test group is calculated by comparing it with the negative control group.

[0148] Bacterial inhibition rate (%) = {[Number of bacteria in negative control (CFU) - Number of bacteria in test group (CFU)] / (Number of bacteria in negative control (CFU))} X 100

[0149]

[0150] - Average viable cell count after 5 minutes (CFU / mL) Bacterial inhibition rate (%) 3HP Concentration (weight%) 0 (Negative control) 2.66 x 10 7 0.000 ± 2.5530.51.720 x 10 7 35.382 ± 1.71311.547 x 10 7 41.901 ± 1.55028.000 x 10 6 69.983 ± 1.68554.333 x 10 3 99.984 ± 0.004PGS (Positive Control)< 1100.000 ± 0.000

[0151] Through the above experiment, a significant (p-value less than 0.001 compared to the negative control group) inhibition rate of acne bacteria was confirmed at the 3HP concentration of the test group compared to the negative control group.

[0152]

[0153] Although the present invention has been described above by limited embodiments, the present invention is not limited thereto, and it is obvious that various modifications and variations are possible within the scope of the technical spirit of the present invention and the equivalent scope of the claims described below by those skilled in the art to which the present invention belongs.

Claims

An acne-fighting cosmetic composition comprising 1,3-hydroxypropionic acid or a derivative thereof as an active ingredient.

2. In Paragraph 1, The above antibacterial cosmetic composition for acne bacteria is an antibacterial cosmetic composition for acne bacteria that exhibits antibacterial activity against Propionibacterium acnes.

3. In Paragraph 1, The above antibacterial cosmetic composition for acne bacteria comprises 0.1% to 10% by weight of the active ingredient based on the total weight of the above antibacterial cosmetic composition for acne bacteria.

4. In Paragraph 1, The above active ingredient is an acne-bacterial cosmetic composition having a radiocarbon isotope content of 20 pMC (percent modern carbon) or more as measured by ASTM D6866-21 and a biocarbon content of 20 weight% or more.

5. In Paragraph 1, The above antibacterial cosmetic composition for acne bacteria further comprises a physiologically acceptable medium.

6. In Paragraph 1, The above antibacterial cosmetic composition for acne bacteria has a formulation that is a solution, suspension, emulsion, paste, gel, cream, lotion, powder, oil, foam, pack, spray, aerosol, balm, solid soap, liquid soap, powder foundation, emulsion foundation, or wax foundation.